| Symbol | ALVOW |
|---|---|
| Name | ALVOTECH |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | 9, RUE DE BITBOURG, LUXEMBOURG, L-1273, Luxembourg |
| Telephone | +352 4224500 |
| Fax | — |
| — | |
| Website | https://www.alvotech.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001898416 |
| Description | Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases. Additional info from NASDAQ: |
Matvæla- og lyfjastofnun Bandaríkjanna (FDA) tekur til afgreiðslu umsókn Alvotech um markaðsleyfi fyrir fyrirhugaða hliðstæðu við Entyvio í sprautu eða lyfjapenna
Read moreAlvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations
Read moreAlvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations
Read moreAlvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
Read moreAlvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
Read moreAlvotech kynnir samning við Lotus Pharmaceutical um markaðssetningu á fyrirhuguðum hliðstæðum við durvalumab og emicizumab í Bandaríkjunum og á völdum mörkuðum í Asíu
Read moreAlvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
Read more